Wed Sep 25 04:18:52 UTC 2024: ## AngioDynamics Emerges as the More Favorable Investment: MarketBeat Analysis

**New York, NY (September 25, 2024) -** MarketBeat News has conducted a comprehensive analysis of medical companies Gerresheimer (OTCMKTS:GRRMF) and AngioDynamics (NASDAQ:ANGO), concluding that AngioDynamics is the more attractive investment option.

The analysis compared the companies across key factors including valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations, and risk.

**Analyst Recommendations:** Analysts are more bullish on AngioDynamics, with a consensus target price of $12.25, representing a potential upside of 61.61%. This indicates a significantly higher potential return compared to Gerresheimer.

**Financial Performance:** While Gerresheimer boasts higher earnings, AngioDynamics generates greater revenue. Additionally, AngioDynamics trades at a lower price-to-earnings ratio, making it more affordable at present.

**Company Profiles:** Gerresheimer specializes in manufacturing and selling medicine packaging, drug delivery devices, and solutions globally. AngioDynamics, on the other hand, focuses on designing, manufacturing, and selling medical devices for treating peripheral vascular disease, oncology, and surgical needs worldwide.

**Conclusion:** The analysis suggests AngioDynamics stands out as the stronger investment choice based on its positive analyst outlook, favorable financial performance, and its focus on innovative medical technology.

**Note:** For a more detailed breakdown of the comparison, including financial tables and company descriptions, please refer to the original MarketBeat News article.

**To receive daily updates on Gerresheimer and related companies, sign up for MarketBeat.com’s FREE daily email newsletter.**

Read More